重组人血管内皮抑制素治疗大鼠子宫内膜异位症的实验研究  

Experimental study of recombinant human endostatin treatment endometriosis in rat

作　　者：马春燕[1] 王振国[1] 万广志[2] 赵爱华[1] 梁玉梅[3] 宋晶莹[3] 

机构地区：[1]解放军第309医院妇产科,北京100091 [2]解放军第309医院肿瘤科,北京100091 [3]解放军第309医院病理科,北京100091

出　　处：《中华临床医师杂志（电子版）》2013年第24期242-245,共4页Chinese Journal of Clinicians(Electronic Edition)

摘　　要：目的分析重组人血管内皮抑制素注射液(恩度)对大鼠子宫内膜异位症新生血管的抑制效果,探索治疗子宫内膜异位症的新手段。方法自体移植法建立子宫内膜异位症动物模型,将子宫内膜异位症大鼠随机分为对照组(腹腔注射等体积生理盐水)、恩度高剂量组(2 mg·kg-1·d-1)、恩度低剂量组(1 mg·kg-1·d-1)。用药治疗2周后,测量异位病灶体积变化,血清中血管内皮生长因子(VEGF)含量,免疫组化法检测异位内膜、正常内膜、在位内膜组织中VEGF表达。结果与对照组相比,恩度治疗组大鼠异位内膜体积缩小,血清中VEGF含量降低,内膜组织中VEGF表达下降,差异有统计学意义(P<0.05)。结论重组人血管内皮抑制素对正常免疫状态大鼠(Wistar大鼠)异位内膜组织新生血管的形成和病灶生长有明显抑制作用,恩度高剂量组治疗大鼠子宫内膜异位症效果更明显。Objective To analysis the effect of Recombinant Human Endostatin Injection （endostar）on angiogenesis in EMs rat, in order to explore a new treatment method of EMs. Methods EMs rats model were established by autologous transplantation methods.Then the rats were randomly divided into control groups received 0.9%NS by intraperitoneal injection, and the treatment group received endostar as above（The endostar high doses group received endostar 2 mg·kg-1·d-1, The endostar low doses group received endostar 1 mg·kg-1·d-1）. The treatment regimen lasted 2 weeks.The volumes of EMs lesion and the levels of Serum VEGF were detected. Immunohistochemistry was used to determine the expression of VEGF in ectopic endometrium, normal endometrium and eutopic endometrium. Results Compared with the control group, the volumes of EMs lesion, the VEGF of Serum and endometrial tissue were decrease in the endostar treatment group. It is more obvious of endostar high doses group（P〈0.05）. Conclusion Recombinant Human Endostatin Injection can effectively interfere with the maintenance and grouth of endometriosis by inhibiting angiogenesis, and endostatin can reduce the expression of VEGF in endometrial tissue of EMs rats with Normal immune system （Wistar rats）, it is more obvious of endostar high doses group.

关 键 词：子宫内膜异位症 血管抑制素类 血管生成抑制剂 大鼠 

分 类 号：R711.71[医药卫生—妇产科学]